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LF rTMS A single session of sham-controlled pre-supplementary motor area 1 Hz rTMS has no effect on levo-
dopa induced dyskinesias.
 It has opposing effects on functional connectivity depending on the dyskinesia state.
 After the ingestion of levodopa, functional patterns were not different from baseline.
a b s t r a c t
Objective: To explore the effects of low-frequency repetitive transcranial magnetic stimulation (LF rTMS)
on cortico-striatal-cerebellar resting state functional connectivity in Parkinson’s disease (PD), with and
without dyskinesias.
Methods: Because there is increasing evidence of an involvement of the pre-supplementary motor area
(pre-SMA) in the pathophysiology of levodopa induced dyskinesias, we targeted the right pre-SMA with
LF rTMS in 17 PD patients. We explored the effects of one sham-controlled LF rTMS session on resting
state functional connectivity of interconnected brain regions by using functional MRI, and how it is mod-
ified by levodopa. The clinical effect on motor function and dyskinesias was documented.
Results: As expected, one LF rTMS session did not alleviate dyskinesias. However, real, and not sham LF
rTMS significantly increased the functional connectivity with the right putamen in patients with dyski-
nesias. In patients without dyskinesias, the real LF rTMS session significantly decreased functional con-
nectivity in the right putamen and the cerebellum. We found no effects on functional connectivity
after levodopa ingestion.
Conclusion: One session of 1 Hz rTMS has opposing effects on pre-SMA functional connectivity depending
on the PD patients’ dyskinesia state.
Significance: Patients dyskinesias state determines the way LF rTMS affects functional connectivity in late
stage PD.
 2021 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights
reserved.1. Introduction
Levodopa-induced dyskinesias (LID) are a complication of long-
term dopamine replacement therapy in patients with Parkinson’s
disease (PD). The past decade, the effect of motor cortex (MC)
low-frequency repetitive transcranial magnetic stimulation (LF
A. Flamez, Guo-Rong Wu, W. Wiels et al. Clinical Neurophysiology 132 (2021) 851–856rTMS) on LID has been investigated in several preliminary studies
yielding conflicting results (for an overview see Flamez et al. 2016).
Functional Magnetic Resonance Imaging (fMRI) studies have
reported inconsistent changes in functional connectivity in the
cerebellar-basal ganglia-cortical pathways in Parkinson disease
brain relative to healthy controls, depending on disease duration,
the presence of certain motor and non-motor features, and the
modulatory effect of dopaminergic therapy (for review see Filippi
et al. 2018). According to a meta-analysis (Herz et al. 2014a), the
most robust task dependent fMRI finding in PD patients is the
reduced activity in the putamen, correlating positively with motor
impairment and improving with dopaminergic treatment. Regard-
ing the activation of cortical areas in PD brain, an altered pre-
supplementary motor area (pre-SMA) activity in PD patients off
medication is invariably present, although that the direction of
the activity alterations (increased versus decreased) is not consis-
tent across studies (Herz et al. 2014a). Resting state functional
MRI (rs-fMRI) is a task independent technique detecting sponta-
neous low-frequency fluctuations in the Blood Oxygenation Level
Dependent (BOLD) signal and diverse analysis methods are used
(seed-based analysis, network-based approach, . . .) to investigate
how PD influences resting state activity and functional connectiv-
ity in the human brain (Prodoehl et al. 2014). Using a network
model Wu et al. (Wu et al. 2009) found an altered functional con-
nectivity in 18 interconnected brain areas important in motor pro-
cesses in PD, including decreases in the supplementary motor area
(SMA) and putamen, and increases in the cerebellum, normalized
by administration of levodopa. Recently, the involvement of the
cerebellum in PD has been highlighted, suggesting not only a
pathological but also a compensatory role (Wu and Hallett 2013).
Morphometric and fMRI evidence argue an involvement of the
prefrontal cortex in the pathophysiology of LID in PD (Cerasa
et al. 2013; Cerasa et al. 2012). Task-related neural activity and
its modification after ingestion of levodopa has been studied using
functional MRI in PD patients with dyskinesias, highlighting the
involvement of putamen and pre-SMA in those patients. In dyski-
netic patients, the intake of levodopa induced a putaminal hyper-
activation starting before any clinical sign of LID was present, as
well as an excessive increase in pre-SMA activity. On top, it seemed
that the pre-SMA was the only cortical area showing increased
responsiveness to levodopa in dyskinetic patients (Herz et al.
2014b; Herz et al. 2015). A rs-fMRI study discovered that levodopa
ingestion differently influences corticostriatal resting state func-
tional connectivity (rsFC) depending on the dyskinesia state of
the PD patient, and that this could be helpful in predicting whether
the patient would develop dyskinesias or not (Herz et al. 2016).
Finally, there is increasing evidence pointing towards a crucial role
of the cerebellum in the generation of LID (Kishore et al. 2014;
Kishore and Popa 2014).
Since rTMS allows for non-invasive modification of underlying
cortical activity, a combined rTMS and fMRI approach has been
used to study rTMS induced changes in brain activity of the tar-
geted cortex and interconnected brain regions in human volun-
teers (Siebner et al. 2009). In late stage PD patients, a recent
combined resting state fMRI/rTMS study showed that a single ses-
sion of continuous theta burst stimulation (cTBS), a patterned rTMS
technique used to decrease excitability of the underlying cortex
(Huang et al. 2005), significantly reduced LID when applied to
the right inferior frontal cortex (IFC) but not to the left MC
(Cerasa et al. 2015). All the above suggests that right centered pre-
frontal areas are involved in the pathophysiological mechanisms of
LID and merit to be further explored in the search for an adequate
treatment of LID.
Therefore, in our present combined rTMS/fMRI study, we inves-
tigated how one sham-controlled session of right pre-SMA LF rTMS
affects resting state functional connectivity in late stage PD852patients with and without dyskinesias. We hypothesized that
depending on the dyskinesia status of the patient, real rTMS (and
not sham) would influence the pre-SMA-striatal-cerebellar FC dif-
ferently. Furthermore, we explored the effects of ingesting a dose
of levodopa on the post rTMS resting state neural activity, motor
function and dyskinesias. Given the one session LF rTMS setup,
we did not expect significant influences on dyskinesias.2. Methods
2.1. Patient population
The study had been approved by The Ethics Committee of the
UZBrussel and all patients provided their written informed con-
sent. Seventeen righthanded patients with the diagnosis of idio-
pathic Parkinson’s disease, according to the United Kingdom
Parkinson’s Disease Society Brain Bank Criteria (Hughes et al.
1992), were enrolled. Patients’ demographics and characteristics
are described in Table 1. Because this study was part of a larger
research project the in- and exclusion criteria for study participa-
tion were reported elsewhere (Flamez et al. 2019).
2.2. Study protocol
We performed each imaging procedure after a 12 hours over-
night dopaminergic treatment withdrawal (practically defined
OFF). We used several imaging techniques in each subject: a struc-
tural MRI, a rs-fMRI scan before (T0) and after the rTMS session
(T1), and 15 and 45 minutes after subsequent ingestion of levodopa
(T2 and T3 respectively) (levodopa challenge test, see below). This
procedure was performed twice in each patient, one containing a
real pre-SMA rTMS session and one sham. Patients were random-
ized to first receive real or sham rTMS by flipping a coin, prior to
the first imaging procedure. To minimize carry-over effects of rTMS
(Rossi et al. 2009) we introduced a time window of at least one
week between both rTMS sessions. Medical treatment remained
unchanged throughout the duration of the trial.
Prior to the imaging procedure and in patients practically
defined OFF state, two blinded raters assessed patients’ motor dis-
ability with the motor part of the Unified Parkinson’s Disease Rat-
ing Scale (UPDRSIII) (Fahn and Elton 1987) and rated dyskinesias
with the modified Abnormal Involuntary Movement Scale (mAIMS)
(Guy 1976). Immediately following the LF rTMS session, a levodopa
challenge test was performed. Patients received 125% of their
morning levodopa equivalent dose as a soluble immediate release
levodopa/benzeraside formulation. Resting state fMRI scans were
performed at 15 (T2) and 45 minutes (T3) after levodopa ingestion.
Subsequently, patients were videotaped, and patients’ motor dis-
ability and dyskinesias were reassessed 60 minutes after levodopa
ingestion (see Fig. 1).
2.2.1. Imaging procedure
During the resting state measurements, involving 7.5 minutes
of scanning, patients were asked to stay awake with their eyes
closed. Scans were performed on a 3 T Philips Achieva MRI system
(Philips, Best, the Netherlands) with an eight-channel SENSE head
coil. An anatomical image was obtained using a 3D T1-weighted
TFE sequence (TR/TE = 12.00/3.71 ms; Flip angle = 10; FOV = 24
0  240  200 mm3; resolution = 1.00  1.00  2.00 mm3; number
of slices = 100). The resting state fMRI measurement was con-
ducted using the SE-EPI sequence (TR/TE = 3000/70 ms; Flip
angle = 90; FOV = 230  230 mm2; resolution = 1.80  1.80 m
m2; Slice thickness/gap = 4.00/1.00 mm; number of slices = 24;
number of dynamics = 150). During resting state fMRI, all patients
were asked to stay awake with their eyes closed.
Table 1
Patients’ baseline characteristics.
Dyskinesia No dyskinesia p-values
Gender (female/male) 4/5 2/6 0.40a
Age (years) 72.89 (9.85) 68.75 (10.73) 0.42b
Disease duration (years) 10.11 (4.37) 11.13 (6.24) 0.70b
Hoehn and Yahr OFFy 3 (2) 2 (1) 0.335c
UPDRSIII OFF* 25.78 (7.79) 19.87 (4.58) 0.081b
LID Yes/No 9 8
Daily equivalent levodopa
dose (mg)
876.67 (410.09) 885.00 (446.19) 0.969b
RMT (%) 55.22 (3.77) 58.50 (4.50) 0.12b
Data are presented as mean (SD) or median values (range) y.
* UPDRSIII in OFF prior to the real rTMS session. There is no significant difference
with the baseline UPDRSIII scores prior to the sham rTMS session (paired t-test
p = 0.95).
LID: levodopa induced dyskinesias; OFF: practically defined OFF after 12 hours
medication withdrawal; RMT: resting motor threshold; UPDRSIII: motor part of the





A. Flamez, Guo-Rong Wu, W. Wiels et al. Clinical Neurophysiology 132 (2021) 851–856The MRI data were analysed with SPM12 software (Wellcome
Department of Cognitive Neurology, London, UK) and the GLMFlex
toolbox. The anatomical images were segmented into grey matter,
white matter, and cerebrospinal fluid. The fMRI images were cor-
rected by slice-timing, realignment, and co-registered to the
anatomical image. The fMRI data are excluded if (1) the maximum
distance of translational movement > 3 mm; (2) the maximum
degree of rotational movement > 3.
Following, all brain volumes were normalized to a standard
MNI template and resampled into 3-mm isotropic voxels.
Several spurious or nonspecific sources of variance were
removed through linear regression of 1) the six head motion
parameters and their temporal derivatives, 2) the non-neuronal
sources of noise estimated using the anatomical component cor-
rection method (aCompCor) (Behzadi et al. 2007; Muschelli et al.
2014), and to remove physiological confounders (heart rate and
respiratory noise) (Whitfield-Gabrieli and Nieto-Castanon, 2012),
3) the first-order Legendre polynomial. Before the voxel-based cor-
relation analysis the residual time series were band-pass filtered
(0.01–0.08 Hz). Here, the right pre-SMA seed region was selected
(6 mm sphere with centre MNI coordinates at x = 2, y = -5,
z = 68). Correlation maps were obtained by extracting the BOLD
time course from pre-SMA, then computing the correlation coeffi-
cient between that time course and the time courses from all the
other brain voxels. The resulting correlation values were converted
into z-scores with Fisher’s z-transform to improve the normality
and smoothed with a 6-mm full-width half-maximum (FWHM)
Gaussian filter.2.2.2. rTMS stimulation protocol
We delivered 1 Hz rTMS to the right pre-SMA with a Magstim
high-speed magnetic stimulator (Magstim Company Limited, Min-
neapolis, USA) through a 70 mm figure-of eight-shaped coil. WeFig. 1. rTMS/fMRI s
853determined the position of the coil, in order to target the pre-
SMA, with our 3D-MRI localization method (Peleman et al. 2010).
Immediately after the baseline rs-fMRI session (T0) was completed,
a series of 1000 pulses at a rate of 1 Hz (duration of 16 minutes) at
90% of the thumb resting motor threshold was applied. The Mag-
stim 70 mm Double Air Film sham coil, identical to its active vari-
ant but without stimulation output, was used for sham
stimulation.
2.3. Statistical analysis
We used SPSS 25 (Statistical Package for the Social Sciences;
IBM Corp., Armonk, NY) for the analysis of all the behavioral
results. To evaluate whether the LF rTMS application affected
Parkinson symptoms (UPDRSIII) and/or dyskinesias (mAIMS), rat-
ings were analyzed separately using a repeated measure analysis
of variance (ANCOVA). Given our recent findings on the relation
between disease duration and LF rTMS effect on pre-SMA neu-
rometabolites (Flamez et al. 2019) also disease duration was intro-
duced as a covariate. The stimulation Condition (sham/real) and
Time (OFF/ON) were the within-subjects’ factors. The between-
subject factor was the presence or absence of dyskinesias (yes/ no).
The pre-SMA seed-based FC maps were submitted to repeated
measures ANCOVA using GLMFlex toolbox, with Dyskinesia (yes/
no) as between-subject factor, and Condition (real/sham) and Time
(Pre- and post rTMS/levodopa) as within-subject factors. Age, gen-
der, mean framewise displacement, and disease duration were set
as covariates. First, to examine the effects of one LF rTMS session
applied to the right pre-SMA, Time was set for the baseline (T0)
and immediately after the LF rTMS session (T1). Second, to explore
the influence of levodopa, Time was set for the baseline (T0) prior
to, and 15 (T2) and 45 minutes (T3) after levodopa ingestion. The
FWE option at cluster level p < 0.05 was set for all analyses to con-
trol for multiple comparisons.
The xjView MATLAB toolbox was used to obtain the anatomical
labels and Montreal Neurological Institute (MNI) coordinates
(http://www.alivelearn.net/xjview).3. Results
3.1. Clinical assessment
As expected, after ingestion of levodopa, UPDRS motor scores
improved in all patients and mAIMS scores increased only in the
dyskinesia group (Table 2). Indeed, the ANCOVA for the UPDRSIII
assessment showed besides a significant main effect of Time (F
(1,14) = 31.89, p < 0.01), no other main or interaction effects for
Condition, Dyskinesia, and Disease duration (p’s > 0.05). Also, the
crucial interaction between Time, Dyskinesia, rTMS Condition
was not significant (F(1,14) = 0.11, p = 0.75). The ANCOVA for the
mAIMS scores showed only a significant interaction effect between
Time and Dyskinesias (F(1,14) = 24.92, p < 0.01), all other main and
interaction effects were not significant (p’s > 0.05). Again, the cru-
cial interaction effect between Time, Dyskinesia, rTMS Condition,
and disease duration was not significant (F(1,14) = 1.26,
p = 0.28). As expected, only in Parkinson patients with LID, at thetudy protocol.
Table 2
Motor function and dyskinesia scores.
OFF ON
Sham Real Sham Real
UPDRSIII
Dyskinesia 25.22 (6.40) 25.78 (7.80) 10.11 (5.44) 10.56 (5.55)
No dyskinesia 20.38 (3.25) 19.88 (4.58) 7.50 (2.00) 7.50 (3.34)
AIMS
Dyskinesia 0.00 (0.00) 0.00 (0.00) 6.11 (4.14) 6.89 (3.62)
No dyskinesia 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00)
Data are presented as mean values (SD).
AIMS: Abnormal Involuntary Movement Scale; OFF: practically defined OFF after 12 hours of medication withdrawal; ON: 1 hour after levodopa ingestion; UPDRSIII: motor
part of the Unified Parkinson’s Disease Rating Scale.
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tests showed a significant increase in AIMS scores after the real
(T(8) = 5.71, p < 0.01) as well as the sham procedure (T(8) = 4.32,
p < 0.01). As expected, no differences after real or sham in this
dyskinesia group were detected (T(8) = 1.08, p = 0.31). AIMS scores
did not significantly change for the PD patients without dyskinesia
(p’s > 0.05). Of note, nonparametric statistical analysis did not
result in different clinical outcomes.3.2. rs-fMRI
The first repeated measures ANCOVA, examining the effects of
one sham-controlled LF rTMS in OFF (before the ingestion of levo-
dopa) with Dyskinesia (yes/no)  Condition (real/ sham LF
rTMS)  Time (T0 and T1), yielded two significant interaction clus-
ters with the (right) pre-SMA: one in the cerebellum (k = 224 vox-
els: MNI coordinates: x = -9 y = -57 z = -6: peak F-value = 15.93;
region: left cerebellar lingual area), and one in the right putamen
(k = 174 voxels: MNI coordinates: x = 15 y = 9 z = 6: peak F-
value = 40.79, region: right putamen) (see Fig. 2). Post hoc analysis
showed that in PD patients without dyskinesias one real LF rTMS
session significantly decreased right pre-SMA rsFC within the right
cerebellum (k = 41 voxels, MNI coordinates: x = 39 y = 36 z = 9,
peak T-value = -3.06) and left cerebellum (k = 20 voxels, MNI coor-
dinates: x = 6 y = 48 z = 6, peak T-value = -4.65), and the right
putamen (k = 62 voxels, MNI coordinates: x = 30 y = 12 z = 0, peak
T-value = -4.13) and that one real LF-rTMS in PD patients with
dyskinesias significantly increased pre-SMA rsFC in the right puta-
men (k = 40 voxels, MNI coordinates: x = 18 y = 6 z = 6, peak T-
value = 5.91). Sham stimulation did not change right pre-SMA rsFC.
More information is provided in the Supplemental Material (Fig-
ure S1). Of note, the use of non-parametric permutation tests
yielded similar results as the repeated measure ANCOVA (Nichols
and Holmes 2002). No scan was removed according to the motion
criteria.
The second repeated measures ANCOVA, exploring the effect of
levodopa ingestion on pre-SMA FC, with
Dyskinesia  Condition  Time (T0, T1, T2 and T3) yielded no signif-
icant interaction clusters, indicating that the ingestion of levodopa
after the LF rTMS session did not differentially affect the pre-SMA
rsFC between the two groups. However, due to motion artifacts we
could only include ten patients (five already had motion artifacts at
T2 and another two PD patients were excluded by motion artifacts
at T3: three in the dyskinesia group and four in the no dyskinesia
group).4. Discussion
To our knowledge, this is the first functional connectivity study
exploring the effect of one session of LF rTMS applied to the right854pre-SMA in late stage PD patients. It was well tolerated but, as
expected, did not alleviate dyskinesias.4.1. Pre-SMA-putaminal functional connectivity
Depending on patients’ dyskinesia state, one session of real, and
not sham pre-SMA LF rTMS yielded opposite effects on pre-SMA-
putaminal functional connectivity. Our results showed that
whereas 1 Hz rTMS increased right pre-SMA FC with the right
putamen in patients suffering from LID, pre-SMA-putaminal FC
decreased in patients without dyskinesias. Because LF rTMS
decreases motor cortex excitability in normal control subjects
when applied directly over the motor cortex (Chen et al. 1997),
and because task-related fMRI studies show that the activity in
the posterior putamen is reduced and the pre-SMA activity is
altered in PD patients (Herz et al. 2014a), inhibitory pre-SMA rTMS
may further reduce putaminal FC in non-dyskinetic patients. On
the contrary, since in dyskinetic PD patients hyperactivity of corti-
cal motor areas has been documented (Rascol et al. 1998), it seems
plausible that inhibitory LF rTMS applied to the pre-SMA results in
FC increases with the ipsilateral putamen. Indeed, in a task related
fMRI trial it has been shown that levodopa intake induces a hyper-
activity of the pre-SMA in the NoGo condition only in the dyski-
netic patients (Herz et al. 2014b), whereas the resting state
functional connectivity between MC/SMA (+pre-SMA) and puta-
men is decreased after levodopa ingestion in LID (Herz et al.
2016). Also, it has been proposed that LID are caused by a maladap-
tive synaptic plasticity (Wang and Zhang 2016). Using a continu-
ous theta burst stimulation protocol Huang and co-workers
demonstrated in PD patients that dopamine is required to induce
long term potentiation (LTP), and that depotentiation could subse-
quently not be induced in the subset of patients suffering from LID
(Huang et al. 2011). Therefore, the loss of depotentiation ability
seems to play a crucial role in the development of LID in PD. Since
there is increasing evidence that rTMS protocols can induce LTP/
LTD like plasticity in the human brain (Huang et al. 2017), we
can speculate that in our dyskinetic patients one session of LF rTMS
on the pre-SMA alters plasticity, hereby improving FC with the
ipsilateral putamen.
Importantly, opposite effects of putaminal FC depending on the
dyskinesia state has already been reported in relation to dopamin-
ergic modulation of cortico-striatal FC in late stage PD patients
(Herz et al. 2016). In this ROI based rsFC study - after the ingestion
of levodopa - functional connectivity between putamen and pri-
mary sensorimotor cortex of the most affected hemisphere
decreased in patients with LID and increased in patients without
LID. Although in our study there was an opposite effect of rTMS
on putaminal FC depending on the dyskinesia state, after the inges-
tion of levodopa, FC patterns were not different from baseline. In
line with Herz’ findings (Herz et al. 2016) one could assume that
levodopa may restore the previously rTMS induced FC changes in
Fig. 2. Sagittal views of the significant interaction effects of full factorial ANOVA, examining the effects of one sham-controlled low frequency repetitive Transcranial
Magnetic Stimulation (LF rTMS) session with Dyskinesia (yes/no)  Condition (real/ sham LF rTMS)  Time (T0 and T1), yielding two significant interaction clusters with the
(right) pre-supplementary motor area (green), in the cerebellum and right putamen (red).
Fig. 3. Coronal views of the significant cerebellar cluster (middle) with the anatomical (left) and functional atlas representation (right) (Buckner et al. 2011).
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preliminary because 15 and 45 minutes after levodopa ingestion
we had to exclude seven participants due to motion artefacts.4.2. Pre-SMA-cerebellar functional connectivity
One session of real, and not sham, pre-SMA LF rTMS signifi-
cantly decreased FC with the somatomotor part of the cerebellum
(Fig. 3) only in patients without dyskinesias. Recent evidence high-
lights the role of the cerebellum in PD (Wu and Hallett 2013). Task
and resting state fMRI studies found an increased neuronal activa-
tion in the cerebellum which was normalized by the administra-
tion of levodopa (Wu et al. 2009; Wu and Hallett 2005). This
could indicate a more compensatory role for the cerebellum in
PD. Compensating for a hypofunctional striato-thalamo-cortical
loop by increasing activity in the cerebello-thalamo-cortical circuit
might be necessary to maintain motor function, at least in the early
stages of the disease (Wu and Hallett 2013). It could also explain
why in our study one session of pre-SMA LF rTMS decreases FC
of the pre-SMA with the cerebellum only in the non-dyskinetic
patients, modulating compensatory mechanisms. Whereas in PD
patients with LID FC with the cerebellum is not altered indicating
a loss of the ability to modulate compensatory cerebellar mecha-
nisms, suggesting that these compensatory mechanisms might be
less effective in those patients.
The role of the cerebellum in the generation of dyskinesias is
supported by other inhibitory cTBS studies (Brusa et al. 2012;
Kishore et al. 2014; Koch et al. 2009). Multiple sessions of bilateral
cerebellar cTBS in PD patients were able to reduce LID for up to
several weeks after the end of the stimulation period. This was
accompanied by a reduction of cerebellar metabolism (Brusa855et al. 2012), or an alteration of motor cortex excitability (Kishore
et al. 2014; Koch et al. 2009). The mechanism however underlying
these induced changes is still unclear.
4.3. Limitations of our study
Of course, the relatively small sample size is a clear limitation,
in spite that the focus of the study was on brain imaging and that
the diagnostic criteria were very stringent. Besides a relatively
small sample size, given the low therapeutic potential of single ses-
sion studies, a multiple LF rTMS session approach could have
yielded more robust effects, on the behavioral level as well as on
pre-SMA FC. Furthermore, we choose to stimulate the right pre-
SMAwhereas in the literature other areas are proposed in the man-
agement of dyskinesias, such as the right IFC (Cerasa et al. 2015) or
the cerebellum (Brusa et al. 2012; Kishore et al. 2014; Koch et al.
2009). Finally, the inclusion of a levodopa challenge test in PD
patients seems challenging given that this resulted in the consider-
able exclusion of rs-fMRI scans due to motion artefacts.
In conclusion, although one session of right pre-SMA LF rTMS
did not alleviate dyskinesias in late stage PD patients, it may have
opposite effects on functional connectivity with the putamen,
depending on their dyskinesia state. Multiple session studies
should be performed to confirm our findings and enhance its ther-
apeutic potential.
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